Aktuelle Therapie der akuten lymphatischen Leukämie des Erwachsenen
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aktuelle Therapie der akuten lymphatischen Leukämie des Erwachsenen
Authors
Keywords
Chemotherapie, Stammzelltransplantation, Molekular zielgerichtete Therapie, Prognose, Minimale Resterkrankung, Chemotherapy, Stem cell transplantation, Molecular targeted therapy, Prognosis, Minimal residual disease
Journal
INTERNIST
Volume 56, Issue 4, Pages 344-353
Publisher
Springer Nature
Online
2015-03-16
DOI
10.1007/s00108-014-3595-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
- (2015) Kathryn G. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
- (2014) D. Hoelzer et al. BLOOD
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- How I treat older patients with ALL
- (2013) N. Gokbuget BLOOD
- Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
- (2012) N. Gokbuget et al. BLOOD
- Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study
- (2012) I.-M. Chen et al. BLOOD
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
- (2012) N. Gokbuget et al. BLOOD
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia
- (2012) H Pfeifer et al. LEUKEMIA
- Acute Lymphoblastic Leukemia: Monitoring Minimal Residual Disease as a Therapeutic Principle
- (2012) Monika Brüggemann et al. SEMINARS IN ONCOLOGY
- High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation
- (2011) N. Gokbuget et al. BLOOD
- Modern Therapy of Acute Lymphoblastic Leukemia
- (2011) Renato Bassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Adult Primary Care after Childhood Acute Lymphoblastic Leukemia
- (2011) Lisa Diller NEW ENGLAND JOURNAL OF MEDICINE
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
- (2009) Monique L Den Boer et al. LANCET ONCOLOGY
- Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
- (2009) M Brüggemann et al. LEUKEMIA
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia
- (2009) Charles G. Mullighan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Adult Acute Lymphoblastic Leukemia
- (2008) Nicola Gökbuget et al. SEMINARS IN HEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More